BRPI0412240A - sistema terapêutico transdérmico com a substáncia ativa pramipexol - Google Patents

sistema terapêutico transdérmico com a substáncia ativa pramipexol

Info

Publication number
BRPI0412240A
BRPI0412240A BRPI0412240-2A BRPI0412240A BRPI0412240A BR PI0412240 A BRPI0412240 A BR PI0412240A BR PI0412240 A BRPI0412240 A BR PI0412240A BR PI0412240 A BRPI0412240 A BR PI0412240A
Authority
BR
Brazil
Prior art keywords
active substance
therapeutic system
transdermal therapeutic
pramipexole
transdermal
Prior art date
Application number
BRPI0412240-2A
Other languages
English (en)
Inventor
Frank Theobald
Wolfgang Laux
Beatrix Platt
Regine Kaufmann
Original Assignee
Lohmann Therapie Syst Lts
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts, Boehringer Ingelheim Pharma filed Critical Lohmann Therapie Syst Lts
Publication of BRPI0412240A publication Critical patent/BRPI0412240A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

"SISTEMA TERAPêUTICO TRANSDéRMICO COM A SUBSTáNCIA ATIVA PRAMIPEXOL". A presente invenção refere-se a um sistema terapêutico transdérmico (TTS) que é capaz de liberar a substância ativa pramipexol durante um período de 4 até 7 dias.
BRPI0412240-2A 2003-07-23 2004-07-14 sistema terapêutico transdérmico com a substáncia ativa pramipexol BRPI0412240A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10333393A DE10333393A1 (de) 2003-07-23 2003-07-23 Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
PCT/EP2004/007770 WO2005011687A1 (de) 2003-07-23 2004-07-14 Transdermales therapeutisches system mit dem wirkstoff pramipexol

Publications (1)

Publication Number Publication Date
BRPI0412240A true BRPI0412240A (pt) 2006-09-12

Family

ID=34088745

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412240-2A BRPI0412240A (pt) 2003-07-23 2004-07-14 sistema terapêutico transdérmico com a substáncia ativa pramipexol

Country Status (11)

Country Link
US (2) US20060182791A1 (pt)
EP (1) EP1651215A1 (pt)
JP (1) JP4925823B2 (pt)
KR (1) KR20060113638A (pt)
CN (1) CN100450482C (pt)
AU (1) AU2004260583B2 (pt)
BR (1) BRPI0412240A (pt)
CA (1) CA2532904A1 (pt)
DE (1) DE10333393A1 (pt)
WO (1) WO2005011687A1 (pt)
ZA (1) ZA200600206B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
PL2026803T3 (pl) 2006-05-16 2012-05-31 Knopp Neurosciences Inc Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
WO2008001200A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal composition having enhanced color stability
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
AU2008224869A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
WO2010010141A1 (en) * 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Pramipexole for treating cardiomyopathy
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
JP5665116B2 (ja) * 2009-11-20 2015-02-04 日東電工株式会社 貼付剤および貼付製剤
JP5652867B2 (ja) * 2009-11-20 2015-01-14 日東電工株式会社 医療用粘着剤組成物
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
DE102012205493A1 (de) 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
US20140045801A1 (en) * 2012-08-09 2014-02-13 Mylan Inc. Pramipexole transdermal delivery for severe headaches
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9682068B2 (en) * 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
WO2015006708A1 (en) 2013-07-12 2015-01-15 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
CN103610666A (zh) * 2013-12-11 2014-03-05 中国药科大学 一种盐酸普拉克索透皮贴剂及其制备方法
MX2016011152A (es) * 2014-02-27 2016-12-09 Medrx Co Ltd Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa.
US9837244B2 (en) * 2014-12-26 2017-12-05 Industrial Technology Research Insitute Sample holding device for studying light-driven reactions and sample analysis method using the same
CN104510725B (zh) * 2015-01-22 2021-04-27 中国药科大学 一种普拉克索周效透皮贴剂及其制备方法
CA3003460A1 (en) * 2016-10-07 2018-04-12 Transwell Biotech Co., Ltd. Pramipexole transdermal delivery system and uses thereof
CN109999012A (zh) * 2019-03-26 2019-07-12 大道隆达（北京）医药科技发展有限公司 一种普拉克索透皮贴剂及其制备方法
CN111904950B (zh) * 2019-05-07 2023-05-05 上海京新生物医药有限公司 一种普拉克索透皮贴剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
WO1996040087A2 (en) * 1995-06-07 1996-12-19 Cygnus, Inc. Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
AU5325000A (en) * 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
JP2003512414A (ja) * 1999-10-28 2003-04-02 スリーエム イノベイティブ プロパティズ カンパニー 経皮薬物送達装置
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
BR0207955A (pt) * 2001-03-07 2004-02-25 Hisamitsu Pharmaceutical Co Agente de emplastro
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol

Also Published As

Publication number Publication date
AU2004260583B2 (en) 2010-01-28
CN1826113A (zh) 2006-08-30
ZA200600206B (en) 2007-02-28
AU2004260583A1 (en) 2005-02-10
CN100450482C (zh) 2009-01-14
DE10333393A1 (de) 2005-02-24
KR20060113638A (ko) 2006-11-02
JP2006528144A (ja) 2006-12-14
WO2005011687A1 (de) 2005-02-10
CA2532904A1 (en) 2005-02-10
US20120225103A1 (en) 2012-09-06
EP1651215A1 (de) 2006-05-03
JP4925823B2 (ja) 2012-05-09
US20060182791A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
BRPI0412240A (pt) sistema terapêutico transdérmico com a substáncia ativa pramipexol
BRPI0400350A (pt) Lancetador compreendendo um sistema de lanceta que é protegido contra reutilização
BR9813360A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz (mmp)
BRPI0515628A (pt) composto de 2-morfolina-4-pirimidona
BRPI0720996B8 (pt) composição adesiva sensível à pressão contendo sal, construto adesivo em camadas, e, dispositivo médico
CL2007003000A1 (es) Compuestos derivados de biaril eter urea; composicion farmaceutica que los contienen; y su uso para el tratamiento de enfermedades o afecciones asociadas a la actividad de amida hidrolasa de acidos grasos (faah).
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
BRPI0507982A (pt) sistema e método para fornecer tratamento a um corpo
HN2006019068A (es) "sintesis de (r)-n-metilnaltrexona"
NI200700107A (es) (bifenil) ácidos carboxílicos y sus derivados
DE602005021141D1 (de) Medizinische vorrichtung zur verabreichung therapeutischer wirkstoffe über unterschiedliche zeitabschnitte
ATE423525T1 (de) Reflektorsystem zur positionsbestimmung
UY26659A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación
PL378035A1 (pl) Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV
BRPI0413540A (pt) moduladores gabanérgicos
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
KR950703953A (ko) 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug)
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
DE60017165D1 (de) Universelle antiinfektionsschutzvorrichtung für nadellose injektoren
IT1293974B1 (it) Dispositivo impiantabile attivo.
WO2014188329A3 (en) Transdermal extended dosing of pramipexole for neurological disorders
BR0015939A (pt) Sistemas terapêuticos transdérmicos com estabilidade aperfeiçoada e um processo para a sua preparação
PT1191927E (pt) Sistema de microrreservatorios a base de polissiloxanos e solventes ambifilicos
AR035889A1 (es) Citrato de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9- pentaeno y composiciones farmaceuticas que la contienen y su uso para la elaboracion de medicamentos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.